Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.

Muccio DD, Atigadda VR, Brouillette WJ, Bland KI, Krontiras H, Grubbs CJ.

Curr Top Med Chem. 2016 Jun 16. [Epub ahead of print]

PMID:
27320329
2.

Retinoid X Receptor Agonists Upregulate Genes Responsible for the Biosynthesis of All-Trans-Retinoic Acid in Human Epidermis.

Wu L, Chaudhary SC, Atigadda VR, Belyaeva OV, Harville SR, Elmets CA, Muccio DD, Athar M, Kedishvili NY.

PLoS One. 2016 Apr 14;11(4):e0153556. doi: 10.1371/journal.pone.0153556.

3.

Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2016 May;15(5):911-21. doi: 10.1158/1535-7163.MCT-15-0521.

PMID:
26873726
4.

Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Atigadda VR, Xia G, Deshpande A, Wu L, Kedishvili N, Smith CD, Krontiras H, Bland KI, Grubbs CJ, Brouillette WJ, Muccio DD.

J Med Chem. 2015 Oct 8;58(19):7763-74. doi: 10.1021/acs.jmedchem.5b00829.

5.

Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2015 Jul;14(7):1559-69. doi: 10.1158/1535-7163.MCT-14-1103.

6.

Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.

Atigadda VR, Xia G, Desphande A, Boerma LJ, Lobo-Ruppert S, Grubbs CJ, Smith CD, Brouillette WJ, Muccio DD.

J Med Chem. 2014 Jun 26;57(12):5370-80. doi: 10.1021/jm5004792.

7.

Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Desphande A, Xia G, Boerma LJ, Vines KK, Atigadda VR, Lobo-Ruppert S, Grubbs CJ, Moeinpour FL, Smith CD, Christov K, Brouillette WJ, Muccio DD.

Bioorg Med Chem. 2014 Jan 1;22(1):178-85. doi: 10.1016/j.bmc.2013.11.039.

8.

Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.

Boerma LJ, Xia G, Qui C, Cox BD, Chalmers MJ, Smith CD, Lobo-Ruppert S, Griffin PR, Muccio DD, Renfrow MB.

J Biol Chem. 2014 Jan 10;289(2):814-26. doi: 10.1074/jbc.M113.476861.

9.
10.

Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R.

Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404.

11.

The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T.

12.

The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.

Whitworth JM, Londoño-Joshi AI, Sellers JC, Oliver PJ, Muccio DD, Atigadda VR, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2012 Apr;125(1):226-30. doi: 10.1016/j.ygyno.2011.12.425.

13.

The use of retinoids in ovarian cancer: a review of the literature.

Whitworth JM, Straughn JM Jr, Atigadda VR, Muccio DD, Buchsbaum DJ.

Int J Gynecol Cancer. 2012 Feb;22(2):191-8. doi: 10.1097/IGC.0b013e318236a2ec. Review.

PMID:
22146768
14.

A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline.

Jackson PL, Noerager BD, Jablonsky MJ, Hardison MT, Cox BD, Patterson JC, Dhanapal B, Blalock JE, Muccio DD.

Eur J Pharmacol. 2011 Oct 15;668(3):435-42. doi: 10.1016/j.ejphar.2011.02.045.

15.

A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.

Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE.

Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70. doi: 10.1158/1940-6207.CAPR-10-0149.

16.

Structure, energetics, and dynamics of binding coactivator peptide to the human retinoid X receptor α ligand binding domain complex with 9-cis-retinoic acid.

Xia G, Boerma LJ, Cox BD, Qiu C, Kang S, Smith CD, Renfrow MB, Muccio DD.

Biochemistry. 2011 Jan 11;50(1):93-105.

17.

Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.

Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM.

Cancer Biol Ther. 2009 Feb;8(3):289-98.

18.

The Novel Retinoid, 9cUAB30, Inhibits Telomerase and Induces Apoptosis in HL60 Cells.

Love WK, Deangelis JT, Berletch JB, Phipps SM, Andrews LG, Brouillette WJ, Muccio DD, Tollefsbol TO.

Transl Oncol. 2008 Sep;1(3):148-52.

19.

In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid.

Gorman GS, Coward L, Kerstner-Wood C, Cork L, Kapetanovic IM, Brouillette WJ, Muccio DD.

Drug Metab Dispos. 2007 Jul;35(7):1157-64.

20.

Conformation of 3'CMP bound to RNase A using TrNOESY.

Lee YC, Jackson PL, Jablonsky MJ, Muccio DD.

Arch Biochem Biophys. 2007 Jul 1;463(1):37-46.

PMID:
17416340
Items per page

Supplemental Content

Loading ...
Support Center